Business Daily from THE HINDU group of publications
Tuesday, Sep 09, 2008
ePaper | Mobile/PDA Version | Audio
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Announcements
Aurobindo gets nod for HIV drug

Hyderabad, Sept. 8

Aurobindo Pharma Ltd has received the tentative approval to manufacture and market Abacavir Sulfate/Lamivudine tablets 600 mg/300 mg from the US Food & Drug Administration (USFDA). Abacavir Sulfate/ Lamivudine tablets 600 mg/300 mg are the generic equivalent of Epzicom tablets 600 mg/300 mg of SmithKline Beecham Corporation and falls under the anti-retroviral segment. The product has been reviewed under the Presidents Emergency Plan for AIDS Relief (PEPFAR). - Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Tests support oral insulin, says Biocon

Aurobindo gets nod for HIV drug
Companies cut conversion price to resolve FCCB tangle
ICSA bags Rs 236-cr worth orders
Nagarjuna Construction-led team bags AP Bhawan project
GM India creates sales company
IIM-K finance meet discusses patterns in M&A deals
Work suspension at Singur will continue: Tata Motors
Stone India plans overseas acquisition
SRF completes Thai acquisition
Greatship, Norwegian co ink pact for sub-sea project
Nuclear action to kick off at Jaitapur, Koodankulam
Igarashi-Bosch venture to start operations soon
Ashok Leyland-Nissan LCV project at ‘zero cost’
Berggruen Hotels ties up with Morocco’s Filacom for global foray
Toyota upbeat on Indian market
Hindujas plan 250-bed hospital in Chennai
Gujarat Govt order weakens State PSUs
‘Private equity investments into India set to increase’
Yamaha plans to expand capacity to 8 lakh units
Asiana Group plans slew of hotels




eWorld
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line